Relieva with Psorberine - Mahonia aquifolium 10%, a homeopathic product - is using IGI's...

BUENA, N.J. -- IGI, INC. (AMEX:IG) announces Apollo Pharmaceuticals product line Relieva(TM) with Psorberine(TM) (Mahonia aquifolium 10%, a homeopathic product) is using with IGI's Novasome(R) Transdermal delivery system.

Relieva(TM), a natural source treatment for plaque psoriasis, is now

"Enrollment has begun for an FDA efficacy study which is expected to last approximately four months. If results match the Company's open trial, Apollo expects to market Relieva(TM) through physicians and OTC outlets," stated Dr. Douglas J. Weiland, M.D., CEO, Apollo Pharmaceuticals.

IGI is applying its patented Novasome(R) microencapsulation technologies to deliver pharmaceuticals, dermaceuticals, cosmetics, skin care, nutrients and other industrial products. Novasomes(R) drive large molecules deep into the skin in a moisturizing non-irritating delayed release cream.

The statements in this release are forward-looking statements that are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including the following: changes in demand for the Company's products, product mix, the timing of customer orders or deliveries, the impact of competitive products and pricing, constraints on supplies of critical components, excess or shortage of production capacity and other risks discussed from time to time in the Company's SEC filings. In addition, such statements could be affected by general industry and market conditions and growth rates, and general domestic and international economic conditions. Such forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the release.